1939-0041/asset/olbannerleft.png?v=1&s=ce302fa1c1aec00bebf120e2be5199ce6074f419)
1939-0041/asset/olbannerright.png?v=1&s=1e6e2d2b7fceba181f8e78e196ba6fe7ddf15982)
Opinion
Nanoparticle therapeutics: a personal perspective
Article first published online: 13 JAN 2009
DOI: 10.1002/wnan.6
Copyright © 2009 John Wiley & Sons, Inc.
Issue
1939-0041/asset/cover.gif?v=1&s=a6c890708514108c90d750634209b5fecaeb4f19 "Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology")
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
Volume 1, Issue 3, pages 264–271, May/June 2009
Additional Information
How to Cite
McNeil, S. E. (2009), Nanoparticle therapeutics: a personal perspective. WIREs Nanomed Nanobiotechnol, 1: 264–271. doi: 10.1002/wnan.6
Publication History
- Issue published online: 17 APR 2009
- Article first published online: 13 JAN 2009
- Abstract
- Article
- References
- Cited By
Abstract
Nanotechnology offers many potential benefits to cancer research through passive and active targeting, increased solubility/bioavailablility, and novel therapies. However, preclinical characterization of nanoparticles is complicated by the variety of materials, their unique surface properties, reactivity, and the task of tracking the individual components of multicomponent, multifunctional nanoparticle therapeutics in in vivo studies. There are also regulatory considerations and scale-up challenges that must be addressed. Despite these hurdles, cancer research has seen appreciable improvements in efficacy and quite a decrease in the toxicity of chemotherapeutics because of ‘nanotech’ formulations, and several engineered nanoparticle clinical trials are well underway. This article reviews some of the challenges and benefits of nanomedicine for cancer therapeutics and diagnostics. © 2009 John Wiley & Sons, Inc.
For further resources related to this article, please visit the WIREs website.